Keytruda Small Cell Lung Cancer

Keytruda is already an established treatment option for non small cell lung cancer and this approval in small cell lung cancer demonstrates our commitment to bringing forward new treatment.

Keytruda small cell lung cancer. Keytruda may be used with the chemotherapy medicines pemetrexed and a platinum as your first treatment when your lung cancer has spread advanced nsclc and is a type called nonsquamous and your tumor does not have an abnormal egfr or alk gene. Findings of the phase 1b keynote 028 trial were published in the journal of clinical oncology. On june 17 2019 the food and drug administration granted accelerated approval to pembrolizumab keytruda merck for patients with metastatic small cell lung cancer sclc with disease. Keytruda is a prescription medicine used to treat a kind of lung cancer called non small cell lung cancer nsclc.

The following information is not intended to endorse any particular medication. Merck co s keytruda may be the star in non small cell lung cancer but a combo of it and chemo just failed to significantly outdo chemo alone at prolonging patients lives in small cell. The immunotherapy agent keytruda pembrolizumab had an overall response rate orr of 33 percent in a recent trial including patients with extensive stage small cell lung cancer sclc.